Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2011-08-30
2011-08-30
Loewe, Sun Jae (Department: 1622)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C546S018000, C546S065000, C546S082000, C546S083000
Reexamination Certificate
active
08008279
ABSTRACT:
The present invention relates to compounds and compositions for treating diseases associated with cysteine protease activity. The compounds are reversible inhibitors of cysteine proteases, including cathepsins B, K, C, F, H, L, O, S, W and X. Of particular interest are diseases associated with Cathepsin K.
REFERENCES:
patent: WO01/09110 (2001-02-01), None
patent: WO01/49288 (2001-07-01), None
patent: WO01/68645 (2001-09-01), None
patent: WO02/069901 (2002-09-01), None
patent: WO03/048123 (2003-06-01), None
patent: WO2004/054987 (2004-07-01), None
patent: WO2004/056324 (2004-07-01), None
Shinozuka et al., Bioorg. Med. Chem. Lett., 2006, 14, 6807-6819.
Neuropathic, http://www.neurology.org/cgi/content/abstract/70/4/263 (2008).
Odanacatib, http://www.drugs.com/clinical—trials/odanacatib-merck-s-investigational-cathepsin-k-inhibitor-reduced-markers-bone-turnover-women-breast-4424.html (2011).
Cai, Jiaqiang et al., “Cathepsin K Inhibitors 2000-2004”, Expert Opinion Ther. Patents, vol. 15, No. 1, pp. 33-48, (2005).
Leroy et al. “Cathepsin S inhibitors” Expert Opin. Ther. Patents. 2004 (14) 301-311.
Palermo et al. “Cysteine cathepsin proteases as pharmacological targets in cancer” Trends in Pharmacological Sciences. 2007 (29) 22-28.
Vasiljeva et al. “Emerging Roles of Cysteine Cathepsins in Disease and their Potential as Drug Targets” Current Pharmacological Sciences. 2007 (13) 387-403.
USPTO Office Action in U.S. Appl. No. 10/538,452, mailed May 5, 2008, 14 pages.
Fish & Richardson P.C., Amendment in Reply to Office Action of May 5, 2008 in U.S. Appl. No. 10/538,452, filed Jul. 11, 2008, 10 pages.
USPTO Final Office Action in U.S. Appl. No. 10/538,452, mailed Oct. 27, 2008, 7 pages.
Fish & Richardson P.C., Amendment in Reply to Final Office Action of Oct. 27, 2008 in U.S. Appl. No. 10/538,452, filed Apr. 22, 2009, 9 pages.
Fish & Richardson P.C., RCE in Reply to Final Office Action of Oct. 27, 2008 in U.S. Appl. No. 10/538,452, filed Apr. 27, 2009, 1 page.
USPTO Notice of Allowance in U.S. Appl. No. 10/538,452, mailed May 18, 2009, 6 pages.
Fish & Richardson P.C., RCE/IDS in reply to Notice of Allowance of May 18, 2009 in U.S. Appl. No. 10/538,452, filed Jun. 3, 2009, 5 pages.
USPTO Notice of Allowance in U.S. Appl. No. 10/538,452, mailed Jun. 19, 2009, 8 pages.
Fish & Richardson P.C., Response to Notice of Allowance of Jun. 19, 2009 in U.S. Appl. No. 10/538,452, filed Sep. 19, 2009, 3 pages.
Chen et al. “Novel pycnodysostosis mouse model uncovers cathepsin K function as a potential regulator of osteoclast apoptosis and senescence” Human Molecular Genetics. 2007 16(4) 410-423.
Lindeman et al. “Cathepsin K is the Principal Protease in Giant Cell Tumor of Bone” Am J Pathol. 2004 (165) 593-600.
Lipton “New therapeutic agents for the treatment of bone diseases” Expert Opin. Biol. Ther. 2005 5(6) 817-832.
McIntyre et al. “Relacatib” Drugs of the Future. 2006 31(5) 406-411.
Pearse “New Strategies for the Treatment of Metastatic Bone Disease” Clinical Breast Cancer Supplement. 2007 (8) S-35-S45.
Skoumal et al. “Serum cathepsin K levels of patients with longstanding rheumatoid arthritis: correlation with radiological destruction” Arthritis Res Ther. 2005 (7) R65-R70.
Wang et al. “Cathepsin K inhibitor—polymer conjugates: potential drugs for the treatment of osteoporosis and rheumatoid arthritis” International Journal of Pharmaceutics. 2004 (277) 73-79.
Wang et al. “Drug delivery strategies for cathepsin inhibitors in joint diseases” Expert Opin. Drug Deliv. 2005 2(6) 1015-1028.
Yasuda et al. “The role of cathepsins in osteoporosis and arthritis: Rationale for the design of new therapeutics” Advanced Drug Delivery Reviews. 2005 (57) 973-993.
Dossetter Alexander Graham
Heron Nicola Murdoch
Astrazeneca AB
Fish & Richardson P.C.
Loewe Sun Jae
LandOfFree
Compound—827 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compound—827, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compound—827 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2711511